Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897412 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
A Phase 2 study of Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 5
- Study locations
NCT04897412 is a Phase 2 study of Subcutaneous Fat that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 75 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT04897412, a Phase 2 study of Subcutaneous Fat, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBL-514 Injection
Study Locations (5)
Illinois
- Investigational site 1 - Chicago
Nebraska
- Investigational site 2 - Omaha
Tennessee
- Investigational site 3 - Nashville
Texas
- Investigational site 4 - Austin
Victoria
- Investigational site 5 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04897412
The ClinicalTrials.gov registry entry for NCT04897412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subcutaneous Fat appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04897412 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Nebraska, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04897412 about?
NCT04897412 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)". The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
What is the current status of trial NCT04897412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2022-02-14. Estimated completion is 2023-03-22.
What conditions does trial NCT04897412 study?
This clinical trial studies the following conditions: Subcutaneous Fat.
What interventions are being tested in trial NCT04897412?
The interventions under investigation include: Placebo (OTHER), CBL-514 Injection (DRUG).
Who is sponsoring clinical trial NCT04897412?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04897412 being conducted?
This trial has 5 study locations across Illinois, Nebraska, Tennessee, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subcutaneous Fat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.